SEC Form 10-K filed by DBV Technologies S.A.
$DBVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2025 | $42.00 | Overweight | Cantor Fitzgerald |
| 12/3/2025 | $35.00 | Buy | Guggenheim |
| 5/29/2025 | $7.25 | Sell | Goldman |
| 1/4/2023 | Hold → Buy | Societe Generale | |
| 12/16/2022 | Neutral → Sell | Goldman | |
| 5/10/2022 | $6.00 → $1.50 | Buy → Neutral | Goldman |
| 12/21/2021 | $8.00 → $5.00 | Market Outperform | JMP Securities |
| 12/21/2021 | $14.00 → $10.00 | Buy | HC Wainwright & Co. |
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the "Company"), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission ("SEC") and its Universal Registration Document (" 2025 URD") with the French market authority, "Autorité des Marchés Financiers" ("AMF"). In compliance with French law, the following information are included in the 2025 URD : The 2025 annual financial report; The Board of Directors' corporate governance report ("rappo
Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Bolstered executive leadership team in preparation for BLA submission and potential approvalReported cash and cash equivalents of $194 million as of December 31, 2025, plus additional gross proceeds of $94 million received on January 16, 2026 —providing funding into the second quarter of 2027 DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today reported financial results for the
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026. "We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets' recognition of our continued progress," stated Daniel Tassé, Chief Executive Officer of D
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
10-K - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00
Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00
Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The changes went into effect on Monday, March 23, 2026. "We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets' recognition of our continued progress," stated Daniel Tassé, Chief Executive Officer of D
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to dateBLA submission in 4-7-year-olds on track for the first half of 2026Achievement
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc
Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD